Liver Disorder Patents (Class 514/893)
-
Patent number: 9034859Abstract: Methods and compositions for the prevention and treatment of liver damage or disease in a subject in need thereof are provided. The methods involve providing the sulfated oxysterol 25-hydroxycholesterol-3-sulfate (25HC3S) to the subject e.g. by 1) administering 25HC3S to the subject; or 2) overexpressing, in the subject, the hydroxysterol sulfotransferase enzyme SULT2B1b, which catalyzes the sulfation of 25-hydroxycholesterol (25HC) to form 25HC3S.Type: GrantFiled: April 6, 2012Date of Patent: May 19, 2015Assignee: Virginia Commonwealth UniversityInventor: Shunlin Ren
-
Patent number: 9023385Abstract: A method of treating a patient to improve liver functioning includes providing a drug composed of at least one of pharmaceutical 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine and a pharmaceutically acceptable salt thereof; and administering the drug to the patient in a manner and dosage effective to improve liver functioning. The 2-(4-morpholinoaniline)-6-cyclohexyl aminopurine can inhibit the activated hepatic stellate cells from synthesizing and expressing collagens and other extracellular matrix proteins including MMPs and TIMPs, and so it can inhibit liver fibrosis. In the liver, it can inhibit collagen synthesis and expression, and therefore reverse and treat hepatitis and liver cirrhosis effectively.Type: GrantFiled: December 2, 2013Date of Patent: May 5, 2015Assignee: Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd.Inventors: Ka Ho Kenneth Lee, Ruohan Chen, Zhibo Hou, Quanwei Pan
-
Patent number: 8969330Abstract: The invention relates to compounds of formula (I): wherein R is ethyl, propyl or allyl, and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof. The compounds of formula (I) are useful as FXR agonists.Type: GrantFiled: February 7, 2013Date of Patent: March 3, 2015Assignee: Intercept Pharmaceuticals, Inc.Inventor: Roberto Pellicciari
-
Patent number: 8920796Abstract: An adsorbent for an oral administration, comprising a surface-modified spherical activated carbon wherein an average diameter is 0.01 to 1 mm, a specific surface area determined by a BET method is 700 m2/g or more, a volume of pores having a pore diameter of 7.5 to 15000 nm is from 0.25 mL/g to 1.0 mL/g, a total amount of acidic groups is 0.30 to 1.20 meq/g, and a total amount of basic groups is 0.20 to 0.7 meq/g, is disclosed.Type: GrantFiled: October 22, 2004Date of Patent: December 30, 2014Assignee: Kureha CorporationInventors: Naohiro Sonobe, Takashi Wakahoi
-
Patent number: 8906964Abstract: The present invention relates to compositions comprising docosapentaenoic acid and methods of reducing lipid parameters, such as triglycerides, total cholesterol, low density lipoprotein (LDL) cholesterol, non-HDL cholesterol, free fatty acids, and other lipids, comprising administration of omega-3 docosapentaenoic acid.Type: GrantFiled: December 9, 2013Date of Patent: December 9, 2014Assignee: Matinas BioPharma, Inc.Inventors: George Bobotas, Abdel Aziz Fawzy
-
Patent number: 8889115Abstract: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs.Type: GrantFiled: October 9, 2012Date of Patent: November 18, 2014Assignee: Relypsa, Inc.Inventors: Dominique Charmot, Han-Ting Chang, Gerrit Klaerner, Jerry M. Buysse, Mingjun Liu
-
Patent number: 8758769Abstract: Disclosed is a composition for preventing and treating acetaminophen induced liver injury including the protein extracted from Porphyra yezoensis. The protein(s), separated and purified from hot water extracts of Porphyra yezoensis, having the molecular weight of 14 kDa measured by sodium dodecyl sulfate polyacrylamide gel electrophoresis, has an excellent effect for inhibiting the oxidative injury of liver tissue and cell apoptosis of liver cells induced by acetaminophen.Type: GrantFiled: August 28, 2007Date of Patent: June 24, 2014Assignee: Pukyong National University Industry Academic Cooperation FoundationInventors: Taek-Jeong Nam, Mi-Jin Kwon, Hye-Jung Hwang
-
Patent number: 8652526Abstract: An astrocyte-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.Type: GrantFiled: April 4, 2012Date of Patent: February 18, 2014Assignee: Nitto Denko CorporationInventors: Yoshiro Niitsu, Junji Kato, Yasushi Sato
-
Patent number: 8642602Abstract: The present invention relates to the discovery of an epigenetic relay pathway that controls hepatic stellate cell activation and the wound-healing response in fibrogenesis, including fibrogenesis of the injured liver. Methods of inhibiting fibrogenesis, including liver fibrogenesis and secondary disease states and conditions thereof, and in treating liver damage, including cirrhosis of the liver (which may be caused by viruses or chemicals, including alcohol), are aspects of the present invention. The methods utilize certain nucleoside compounds and/or antibodies which are optionally conjugated. Pharmaceutical compositions represent additional aspects of the invention.Type: GrantFiled: February 2, 2010Date of Patent: February 4, 2014Assignees: University of Georgia Research Foundation, Inc., University of Newcastle Upon TyneInventors: Jelena Mann, Chung K. Chu, Derek A. Mann
-
Patent number: 8603470Abstract: Reducing liver fibrosis in a subject having or being suspected of having a liver disease using an IL-20 antagonist, which can be an antibody that blocks a signaling pathway mediated by IL-20. Such antibodies include anti-IL-20 antibodies and anti-IL-20R antibodies that specifically block the IL-20 signaling pathway.Type: GrantFiled: August 7, 2012Date of Patent: December 10, 2013Assignee: National Cheng Kung UniversityInventor: Ming-Shi Chang
-
Patent number: 8591953Abstract: An astrocyte-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.Type: GrantFiled: April 4, 2012Date of Patent: November 26, 2013Assignee: Nitto Denko CorporationInventors: Yoshiro Niitsu, Junji Kato, Yasushi Sato
-
Patent number: 8518447Abstract: The methods for treatment using an adsorbent having a high adsorbability, and capable of adsorbing a large amount of toxins during a retention period in an intestine, and of remarkably increasing an adsorption amount of compounds having a large molecular weight.Type: GrantFiled: February 25, 2013Date of Patent: August 27, 2013Assignee: Kureha CorporationInventors: Naohiro Sonobe, Takashi Wakahoi, Mieko Kuwahara
-
Patent number: 8409561Abstract: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising sodium-binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, chronic renal insufficiency, fluid overload, or sodium overload.Type: GrantFiled: August 16, 2010Date of Patent: April 2, 2013Assignee: Relypsa, Inc.Inventors: Dominique Charmot, Han-Ting Chang, Mingjun Liu, Futian Liu, Gerrit Klaerner
-
Patent number: 8377916Abstract: The invention relates to compounds of formula (I): wherein R is ethyl, propyl or allyl, and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof. The compounds of formula (I) are useful as FXR agonists.Type: GrantFiled: November 3, 2011Date of Patent: February 19, 2013Assignee: Intercept Pharmaceuticals, Inc.Inventor: Roberto Pellicciari
-
Patent number: 8329661Abstract: This invention is based on the experimental finding that HIP/PAP has mitogenic and antiapoptotic effects in vitro on hepatocytes in primary culture. Moreover, HIP/PAP is a mitogenic and anti-apoptotic molecule for hepatocytcs, in vivo, during liver failure and liver regeneration. The present invention is also based on the experimental finding that HIP/PAP administration has no adverse effects in mammals. This invention concerns a pharmaceutical composition for stimulating liver regeneration in vivo including after chronic/acute liver failure, comprising an effective amount of a polypeptide comprising an amino acid sequence having 90% amino acid identity with the polypeptide consisting of the amino acid sequence starting at the amino acid residue (36) and ending at the amino acid residue (175) of sequence SEQ ID No 1, in combination with at least one physiologically acceptable excipient.Type: GrantFiled: February 22, 2011Date of Patent: December 11, 2012Assignees: Instiut National de la Santéet de la Recherche Médicale (INSERM), Universite Rene DescartesInventors: Laurence Christa, Christian Brechot, Marie-Thérèse Simon-Gage-Soufflot, Alain Pauloin, J. Guilherme Tralhao
-
Patent number: 8178124Abstract: An astrocyte-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.Type: GrantFiled: September 29, 2011Date of Patent: May 15, 2012Assignee: Nitto Denko CorporationInventors: Yoshiro Niitsu, Junji Kato, Yasushi Sato
-
Patent number: 8173170Abstract: An astrocyte-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.Type: GrantFiled: December 22, 2005Date of Patent: May 8, 2012Assignee: Nitto Denko CorporationInventors: Yoshiro Niitsu, Junji Kato, Yasushi Sato
-
Patent number: 8017622Abstract: The present invention relates to opioid and opioid-like compounds, and pharmaceutical formulations thereof, and use thereof for prevention and treatment of disorders such as septic shock and organ damage.Type: GrantFiled: March 9, 2009Date of Patent: September 13, 2011Assignee: Jenken Biosciences, Inc.Inventors: Edwin S. C. Wu, Mao-Hsiung Yen
-
Patent number: 7786102Abstract: The invention relates to compounds of formula (I): wherein R is ethyl, and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof. The compounds of formula (I) are useful as FXR agonists.Type: GrantFiled: November 21, 2006Date of Patent: August 31, 2010Assignee: Intercept Pharmaceuticals, Inc.Inventor: Roberto Pellicciari
-
Patent number: 7776319Abstract: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising sodium-binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, chronic renal insufficiency, fluid overload, or sodium overload.Type: GrantFiled: March 30, 2005Date of Patent: August 17, 2010Assignee: Relypsa, Inc.Inventors: Robert Alpern, Jerry Buysse, Han Ting Chang, Dominique Charmot, Michael James Cope, John Fordtran, Gerrit Klaerner, Eric Connor, Mingjun Liu, Futian Liu, Jun Shao
-
Patent number: 7588776Abstract: A pharmaceutical composition containing a water-soluble fraction of Graptopetalum and its use in treating a liver disease or condition, such as inflammation, steatosis, and fibrosis.Type: GrantFiled: February 27, 2008Date of Patent: September 15, 2009Inventor: Shih-Lan Hsu
-
Patent number: 7501392Abstract: The invention relates to the use of interferon alpha 5 in the treatment of viral hepatopathies. The invention describes the reduced synthesis of IFN?5 in the livers of patients with hepatitis C in comparison to healthy livers. The sub-type of IFN expressed in said healthy livers corresponded only to the subtype alpha 5 in comparison with the different sub-types expressed in ill livers. The sequence SEQ ID NO:1 shows the partial sequence of cDNA corresponding to IFN?5. These significant differences between the expression patterns of some livers an others demonstrate the importance of the use of such interferon sub-type in the fabrication of compositions useful in the treatment of viral hepatopathies. The invention discloses in details such utilization in different forms and processes, including those which use the production of recombinant proteins from sequences of the type SEQ ID NO:1.Type: GrantFiled: August 25, 2005Date of Patent: March 10, 2009Assignee: Proyecto de Biomedicina Cima, S.L.Inventors: Jesús Prieto Valtueña, Ma Pilar Civeira Murillo, Esther Larrea Leoz
-
Patent number: 7419689Abstract: The present invention is directed to plant based formulations for improving liver health by protecting the liver from alcohol and chemical insults and/or by inducing phase II enzymes. Formulations according to the present invention include wasabi root fiber powder, artichoke leaf extract, asparagus dehydrate, kudzu root extract, oregano extract, schisandra berry extract, notoginseng (ethanol extract of Panax notoginseng root), sanchi (water extracts from Panax notoginseng root), Gegen root extract (Pueraria omeiensis), spinach dehydrate, or combinations thereof.Type: GrantFiled: November 15, 2005Date of Patent: September 2, 2008Assignee: Access Business Group International LLC.Inventors: Chioma Jane Ikonte, Michael Huang, Cherie L. Hacker, Silvia R. da Costa, Paul D. Johnson, Amitabh Chandra, Christine M. Paganelli, Ruo G. Huang
-
Patent number: 7364758Abstract: The present invention relates to compositions comprising Graptopetalum and uses thereof Graptopetalum can protect animals from liver diseases and medical conditions, such as inflammation, steatosis, and fibrosis. In particular, Graptopetalum inhibits proliferation of activated hepatic stellate cells, which play a pivotal role in liver fibrosis. Graptopetalum also has anti-fibrosis activities as well as inhibits proliferation of lung fibroblasts. Therefore, in addition to being a prophylactic and therapeutic agent for the liver, Graptopetalum is useful against fibrosis or inflammation of tissues or organs other than the liver, in particular lung, kidney, and bladder. Other plants in the family of Crassulaceae, particularly Echeveria, have similar effects as Graptopetalum.Type: GrantFiled: August 31, 2004Date of Patent: April 29, 2008Inventor: Shih-Lan Hsu
-
Patent number: 7335642Abstract: A method of modulating cytokine mediated hepatic injury by administering compound-D SEQ ID NO:1 to a mammal. A concentration of the compound in the range of about 0.5 mg/kg to about 20 mg/kg in a physiologically acceptable formulation blocks a cytokine cascade. A therapeutic method of modulating cytokine mediated acute inflammatory, trauma induced and toxin induced hepatic injury, particularly via tumor necrosis factor modulation, is thus disclosed.Type: GrantFiled: March 22, 2005Date of Patent: February 26, 2008Assignee: University of Kentucky Research FoundationInventors: Peter R. Oeltgen, Paul D. Bishop, Craig J. McClain, Shirish Barve
-
Patent number: 7132450Abstract: A hepatic disorder suppressant comprising extracts having hepatic disorder suppressing effect as effective ingredients, wherein the extracts is obtained by extracting an avocado plant and/or a processed product thereof with an organic solvent is disclosed.Type: GrantFiled: March 25, 2005Date of Patent: November 7, 2006Assignee: Kagome Co., Ltd.Inventors: Yasushi Arimoto, Hiroyuki Suganuma, Takahiro Inakuma, Kimio Sugiyama, He Puming, Hirokazu Kawagishi
-
Patent number: 7122541Abstract: The invention relates to methods for preventing and treating disseminating cancers. Inhibition metastases of a primary tumor to a liver tissue is carried out by directly contacting a liver tissue with Taurolidine.Type: GrantFiled: June 21, 2004Date of Patent: October 17, 2006Assignee: Rhode Island HospitalInventors: Jack R. Wands, Rolf I. Carlson, Paul Maggio
-
Patent number: 7101913Abstract: A hepatic disorder suppressant comprising extracts having hepatic disorder suppressing effect as effective ingredients, wherein the extracts is obtained by extracting an avocado plant and/or a processed product thereof with an organic solvent is disclosed.Type: GrantFiled: March 25, 2005Date of Patent: September 5, 2006Assignee: Kagome Co., Ltd.Inventors: Yasushi Arimoto, Hiroyuki Suganuma, Takahiro Inakuma, Kimio Sugiyama, He Puming, Hirokazu Kawagishi
-
Patent number: 7081480Abstract: A hepatic disorder suppressant comprising extracts having hepatic disorder suppressing effect as effective ingredients, wherein the extracts is obtained by extracting an avocado plant and/or a processed product thereof with an organic solvent is disclosed.Type: GrantFiled: March 25, 2005Date of Patent: July 25, 2006Assignee: Kagome Co., Ltd.Inventors: Yasushi Arimoto, Hiroyuki Suganuma, Takahiro Inakuma, Kimio Sugiyama, He Puming, Hirokazu Kawagishi
-
Patent number: 7078064Abstract: The invention relates generally to compositions comprising antioxidants useful for reducing oxidative stress and lipid peroxidation, and treating chronic liver disease, chronic hepatitis C virus infection and non-alcoholic steatohepatitis. In particular, the invention relates to the preparation and oral administration of compositions comprising glycyrrhizin, schisandra, ascorbic acid, L-glutathione, silymarin, lipoic acid, and d-alpha-tocopherol. The invention also relates to the preparation and parenteral administration of compositions comprising glycyrrhizin, ascorbic acid, L-glutathione, and vitamin B-complex, preferably by infusion or intravenous injection. The invention further relates to methods of using the antioxidants, oral compositions and parenteral compositions.Type: GrantFiled: December 3, 2003Date of Patent: July 18, 2006Inventor: George Zabrecky
-
Patent number: 7060262Abstract: Immune stimulatory amounts of hematopoietic colony stimulating factors are administered to patients with inflammatory bowel disease. The factors include G-CSF and GM-CSF. These factors induce and maintain remission of the disease and its manifestations, whether within the intestine or without.Type: GrantFiled: October 1, 2002Date of Patent: June 13, 2006Assignee: The Washington UniversityInventors: Brian K. Dieckgraefe, Joshua Korzenik
-
Patent number: 6995133Abstract: The invention relates to the use of interferon alpha 5 in the treatment of viral hepatopathies. The invention describes the reduced synthesis of IFN?5 in the livers of patients with hepatitis C in comparison to healthy livers. The sub-type of IFN expressed in said healthy livers corresponded only to the subtype alpha 5 in comparison with the different sub-types expressed in ill livers. The sequence SEQ ID NO:1 shows the partial sequence of cDNA corresponding to IFN?5. These significant differences between the expression patterns of some livers an others demonstrate the importance of the use of such interferon sub-type in the fabrication of compositions useful in the treatment of viral hepatopathies. The invention discloses in details such utilization in different forms and processes, including those which use the production of recombinant proteins from sequences of the type SEQ ID NO:1.Type: GrantFiled: May 13, 1999Date of Patent: February 7, 2006Assignee: Proyecto de Biomedicina CIMA, S.L.Inventors: Jesús Prieto Valtueña, Ma Pilar Civeira Murillo, Esther Larrea Leoz
-
Patent number: 6989162Abstract: A process of isolation of pure Acteoside of high hepatoprotection from plant Colerbrookea oppositifolia, said process comprising steps of drying aerial parts of the plant, grounding the dried parts into powder, percolating the powder with water or ethanol for 3-4 times to obtain an extract, filtering the extract for clearing of suspended particles to obtain supernatant, drying the supernatant at about 45 to 55° C.Type: GrantFiled: March 31, 2003Date of Patent: January 24, 2006Assignee: Council of Scientific & Industrial ResearchInventors: Ghulam Nabi Qazi, Om Parkash Suri, Kasturi Lal Bedi, Krishan Avtar Suri, Bishan Datt Gupta, Bupinder Singh Jaggi, Bal Krishan Kapahi, Naresh Kumar Satti, Musarat Amina, Bal Krishan Chandan, Neelam Sharma, Gurdarshan Singh
-
Patent number: 6942882Abstract: A hepatic disorder suppressant comprising extracts having hepatic disorder suppressing effect as effective ingredients, wherein the extracts is obtained by extracting an avocado plant and/or a processed product thereof with an organic solvent is disclosed.Type: GrantFiled: October 11, 2002Date of Patent: September 13, 2005Assignee: Kagome Co., Ltd.Inventors: Yasushi Arimoto, Hiroyuki Suganuma, Takahiro Inakuma, Kimio Sugiyama, He Puming, Hirokazu Kawagishi
-
Patent number: 6875742Abstract: A method of modulating cytokine mediated hepatic injury by administering compound-D SEQ ID NO:1 to a mammal. A concentration of the compound in the range of about 0.5 mg/kg to about 20 mg/kg in a physiologically acceptable formulation blocks a cytokine cascade. A therapeutic method of modulating cytokine mediated acute inflammatory, trauma induced and toxin induced hepatic injury, particularly via tumor necrosis factor modulation, is thus disclosed.Type: GrantFiled: October 5, 2001Date of Patent: April 5, 2005Assignees: ZymoGenetics, Inc., University of Kentucky Research FoundationInventors: Peter R. Oeltgen, Paul D. Bishop, Craig J. McClain, Shirish Barve
-
Patent number: 6863904Abstract: The present invention relates to compositions without added iron and methods for prophylactic nutritional supplementation and therapeutic nutritional supplementation. Specifically, the method involves administering to an individual a composition comprising carotenoids, vitamin E, vitamin D, vitamin C, thiamine, riboflavin, niacin, folic acid, pyridoxine, biotin, pantothenic acid, cobalamin, magnesium, manganese, zinc, selenium, chromium, copper, alpha lipoic acid, and lutein, wherein the composition is free of added iron.Type: GrantFiled: October 14, 2003Date of Patent: March 8, 2005Assignee: Everett Laboratories, Inc.Inventors: John A. Giordano, Charles Balzer
-
Patent number: 6770635Abstract: Adverse inflammatory reactions can be treated by administrating to an organism a composition having diglucosylamine as the active ingredient. The preferred compound is di-Beta-D-glucopyranosylamine. A simple method for making diglucosylamine in high purity is obtained by reacting glucose, a nitrogen containing base, and either methanol or ethanol to form the diglucosylamine and then recovering the diglucosylamine preferably with the use of charcoal. The preferred diglucosylamine, di-Beta-D-glucopyranosylamine, has extraordinary anti-inflammatory activity. It can be formulated with a pharmaceutically acceptable carrier to make pharmaceutical compositions which are effective in treating inflammations. This pharmaceutical composition can also be used to treat adverse inflammatory reactions that are the result of the disruptions of a dynamic network of cellular mechanisms in organisms.Type: GrantFiled: December 4, 1997Date of Patent: August 3, 2004Assignee: Pharos PharmaceuticalsInventor: Clairmont G. Drube
-
Patent number: 6753328Abstract: The invention relates to methods for preventing and treating disseminating cancers. Inhibition metastases of a primary tumor to a liver tissue is carried out by directly contacting a liver tissue with Taurolidine.Type: GrantFiled: October 1, 2002Date of Patent: June 22, 2004Assignee: Rhode Island HospitalInventors: Jack R. Wands, Rolf I. Carlson, Paul Maggio
-
Patent number: 6719969Abstract: Disclosed is the surprising discovery that CXC chemokines function to induce rapid hepatocyte proliferation and liver regeneration after injury. The invention thus provides a range of compositions and methods for use in treating liver injury, including those suitable for treating acetaminophen overdose outside the therapeutic window for N-acetyl-cysteine treatment, and those that limit the hepatotoxic side-effects of gene therapy regimens.Type: GrantFiled: August 4, 2000Date of Patent: April 13, 2004Assignees: The Regents of The University of Michigan, University Court of The University of EdinburghInventors: Cory M. Hogaboam, Cynthia L. Bone-Larson, Kenneth J. Simpson, Nicholas W. Lukacs, Steven L. Kunkel, Lisa M. Colletti, Robert M. Strieter
-
Patent number: 6685931Abstract: The hepatoprotective effect of IL-10 is described, in particular, the use of interleukin-10 in the treatment of liver damage (e.g. fibrosis or cirrhosis) in a difficult-to-treat patient afflicted with chronic hepatitis C virus infection who has failed to respond to, or achieve a sustained virologic response to an anti-HCV therapy(e.g., interferon-&agr; in combination with ribavirin).Type: GrantFiled: December 20, 1999Date of Patent: February 3, 2004Assignee: Schering CorporationInventors: Paul C. Grint, David R. Nelson, Gary L. Davis
-
Patent number: 6686332Abstract: The present invention provides methods of treating adverse physiological effects associated with depressed reticuloendothelial system function comprising administering to a subject suffering from depressed reticuloendothelial system function an effective amount of a BPI protein product.Type: GrantFiled: October 12, 2000Date of Patent: February 3, 2004Assignee: Xoma CorporationInventors: Paul A. M. van Leeuwan, Marja A. Boermeester
-
Patent number: 6686375Abstract: The present invention relates to a composition useful for hepatoprotection, said composition comprising polar extract of plant Cryptolepis Buchanani and/or fractions of the said extract, and optionally pharmaceutically acceptable additives and a method of producing said composition and also a method of treating a subject using said composition.Type: GrantFiled: March 26, 2002Date of Patent: February 3, 2004Assignee: Council of Scientific and Industrial ResearchInventors: Ghulam Nabi Qazi, Bupinder Singh Jaggi, Bal Krishan Chandan, Krishnan Avtar Suri, Naresh Kumar Satti, Rakesh Maurya, Lila Ram Manhas, Ashwani Kumar, Bal Krishnan Kapahi
-
Patent number: 6592910Abstract: The present invention provides a method of treating or preventing certain medical conditions with isoflavones. More specifically, the invention provides a method of treating or preventing one or more of the following medical conditions: hepatic steatosis, steatohepatitis, insulin resistance, impaired glucose tolerance, syndrome X, abnormal platelet function, or abnormal vascular reactivity, with compositions containing isoflavones.Type: GrantFiled: April 20, 2000Date of Patent: July 15, 2003Assignee: Board of Trustees, Southern Illinois UniversityInventors: William J. Banz, Michael R. Peluso, Todd A. Winters, Michael F. Shanahan
-
Patent number: 6593364Abstract: A triterpene derivative useful for the treatment of hepatic disorders is disclosed. This compound comprises as an active ingredient a triterpene derivative represented by the following formula (I) or a salt thereof: wherein R1 represents a hydroxyl group, arylmethyloxy, lower alkoxy, or lower alkanoyloxy, R2 represents lower alkyl, lower alkenyl, —CH2OR5, formyl, —COOR6, or —CH2N(R7)R8, or R1 and R2 may combine with each other to form —O—C(R9)R10—O—CH2—, R3 and R4, which may be the same or different represent a hydrogen atom, a hydroxyl group, lower alkyl, lower alkenyl, aryl, hydroxymethyl, —N(R11)R12, formyl, —COOR6, or —OR13, or R3 and R4 may combine with each other to form oxo, hydroxyimino, or alkylidene and X represents O, CH2, or NH.Type: GrantFiled: August 6, 2001Date of Patent: July 15, 2003Assignee: Meiji Seika Kaisha, Ltd.Inventors: Kazue Sasaki, Nobuto Minowa, Shoji Nishiyama, Hiroyuki Kuzuhara
-
Patent number: 6585974Abstract: An agent protective against drug-induced hepatopathy containing Lentinus edodes mycelium extract.Type: GrantFiled: August 15, 2001Date of Patent: July 1, 2003Assignees: Kobayashi Pharmaceutical Co., Ltd.Inventors: Katsuyuki Fujimura, Yasuyo Yamaguchi, Reiko Sugino, Hideki Shirogane, Toyomi Takeuchi
-
Patent number: 6552070Abstract: A health food/dietary supplement is disclosed, endowed with a protective action on liver function against exogenous and endogenous hepatoxic agents, the characterizing components of which are isovaleryl L-carnitine and/or propionyl L-carnitine and an extract of Silybum marianum (milk thistle) standardized to a least 70 percent by weight of silymarin.Type: GrantFiled: March 4, 2002Date of Patent: April 22, 2003Assignee: Sigma-Tau HealthScience S.p.A.Inventor: Pietro Pola
-
Patent number: 6544954Abstract: The present invention provides stable galactose injection solutions, which contain 1 to 50% by weight of galactose, 0.01 to 1 M of a buffer solution, and 0.01 to 5% of an antioxidant. The preferred buffer solution is citrate buffer. The preferred anti-oxidant is sodium bisulfite. The galactose injection solution of the present invention has a pH between 4.0 and 9.0 and is stable at 80° C. for at least 2 weeks.Type: GrantFiled: February 19, 2002Date of Patent: April 8, 2003Inventors: Oliver Yoa-Pu Hu, Cheng-Huei Hsiong
-
Patent number: 6524610Abstract: A nutritional composition made from conventional food mixed on-site in a blender and treating patients with hepatic disorders.Type: GrantFiled: February 26, 2001Date of Patent: February 25, 2003Inventor: Julia Muszynska
-
Patent number: 6514963Abstract: The present invention comprises methods and compositions for use in inhibiting egg production by parasitic trematode worms comprising administering to an individual in need thereof an effective amount of an agent which transiently inhibits the influx of calcium through a cell membrane calcium channel. Inhibition of egg production in the worms ameliorates many of the symptoms and pathology related to infection by trematode related diseases, including Schistosomiasis. The methods can also effect disease transmission by reducing the number of eggs released into the environment available to continue the worm life cycle.Type: GrantFiled: July 18, 2001Date of Patent: February 4, 2003Assignee: The Regents of the University of CaliforniaInventors: Mark Walter, Armand Kuris
-
Patent number: 6500418Abstract: Immune stimulatory amounts of hematopoietic colony stimulating factors are administered to patients with inflammatory bowel disease. The factors include G-CSF and GM-CSF. These factors induce and maintain remission of the disease and its manifestations, whether within the intestine or without.Type: GrantFiled: August 11, 2000Date of Patent: December 31, 2002Assignee: The Washington UniversityInventors: Brian Dieckgraefe, Joshua Korzenik